JP4253439B2 - アポトーシスを誘発しおよび／または炎症反応を低下するためのアルギニン・デイミナーゼに富む細菌の使用、および該細菌を含有する医薬組成物または健康食組成物 - Google Patents
アポトーシスを誘発しおよび／または炎症反応を低下するためのアルギニン・デイミナーゼに富む細菌の使用、および該細菌を含有する医薬組成物または健康食組成物 Download PDFInfo
- Publication number
- JP4253439B2 JP4253439B2 JP2000532508A JP2000532508A JP4253439B2 JP 4253439 B2 JP4253439 B2 JP 4253439B2 JP 2000532508 A JP2000532508 A JP 2000532508A JP 2000532508 A JP2000532508 A JP 2000532508A JP 4253439 B2 JP4253439 B2 JP 4253439B2
- Authority
- JP
- Japan
- Prior art keywords
- lactobacillus
- bifidobacterium
- bacteria
- composition
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108010082340 Arginine deiminase Proteins 0.000 title claims description 25
- 239000000203 mixture Substances 0.000 title claims description 10
- 235000013402 health food Nutrition 0.000 title claims description 5
- 241000894006 Bacteria Species 0.000 title description 28
- 230000006907 apoptotic process Effects 0.000 title description 20
- 230000028709 inflammatory response Effects 0.000 title description 4
- 230000000694 effects Effects 0.000 claims description 18
- 241000186660 Lactobacillus Species 0.000 claims description 17
- 229940039696 lactobacillus Drugs 0.000 claims description 17
- 241000186000 Bifidobacterium Species 0.000 claims description 14
- 239000004475 Arginine Substances 0.000 claims description 11
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 11
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 11
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 11
- 229960002173 citrulline Drugs 0.000 claims description 11
- 235000013477 citrulline Nutrition 0.000 claims description 11
- 244000005700 microbiome Species 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000007246 mechanism Effects 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- 241000157921 Actinotalea fermentans Species 0.000 claims description 2
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 2
- 241000186012 Bifidobacterium breve Species 0.000 claims description 2
- 241001608472 Bifidobacterium longum Species 0.000 claims description 2
- 241000186148 Bifidobacterium pseudolongum Species 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 244000199866 Lactobacillus casei Species 0.000 claims description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 2
- 241001438705 Lactobacillus rogosae Species 0.000 claims description 2
- 241000194037 Lactococcus raffinolactis Species 0.000 claims description 2
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims description 2
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 2
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- 150000001783 ceramides Chemical class 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 229940017800 lactobacillus casei Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 239000013589 supplement Substances 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 241000193815 Atopobium minutum Species 0.000 claims 1
- 241001478240 Coccus Species 0.000 claims 1
- 241001134720 Rhodoferax fermentans Species 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000000677 immunologic agent Substances 0.000 claims 1
- 229940124541 immunological agent Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000006041 probiotic Substances 0.000 claims 1
- 230000000529 probiotic effect Effects 0.000 claims 1
- 235000018291 probiotics Nutrition 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 21
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 18
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 17
- 238000011282 treatment Methods 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 9
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 9
- 235000014655 lactic acid Nutrition 0.000 description 9
- 239000004310 lactic acid Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 240000001929 Lactobacillus brevis Species 0.000 description 5
- 241000204031 Mycoplasma Species 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 4
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 4
- 206010028851 Necrosis Diseases 0.000 description 4
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 4
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000017074 necrotic cell death Effects 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 241001134654 Lactobacillus leichmannii Species 0.000 description 3
- 208000002389 Pouchitis Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000589774 Pseudomonas sp. Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229960004295 valine Drugs 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 241000186018 Bifidobacterium adolescentis Species 0.000 description 1
- 241000186014 Bifidobacterium angulatum Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186011 Bifidobacterium catenulatum Species 0.000 description 1
- 241000186020 Bifidobacterium dentium Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241001134772 Bifidobacterium pseudocatenulatum Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001430190 Eggerthia catenaformis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical compound NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000186679 Lactobacillus buchneri Species 0.000 description 1
- 241000218492 Lactobacillus crispatus Species 0.000 description 1
- 241001134659 Lactobacillus curvatus Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241001561398 Lactobacillus jensenii Species 0.000 description 1
- 241000186869 Lactobacillus salivarius Species 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000605082 Saccharicrinis fermentans Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 235000014897 Streptococcus lactis Nutrition 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 206010047163 Vasospasm Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008578 acute process Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940094957 androgens and estrogen Drugs 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229940124378 dental agent Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 201000005991 hyperphosphatemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 239000003471 mutagenic agent Substances 0.000 description 1
- 231100000707 mutagenic chemical Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000000173 nephrocalcinosis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- -1 patches Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 201000003437 pleural cancer Diseases 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000008189 vertebrate development Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT98RM000103A IT1298918B1 (it) | 1998-02-20 | 1998-02-20 | Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche |
| IT98A000103 | 1998-02-23 | ||
| PCT/IT1998/000275 WO1999042568A1 (en) | 1998-02-20 | 1998-10-13 | Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002504324A JP2002504324A (ja) | 2002-02-12 |
| JP4253439B2 true JP4253439B2 (ja) | 2009-04-15 |
Family
ID=11405583
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000532508A Expired - Fee Related JP4253439B2 (ja) | 1998-02-20 | 1998-10-13 | アポトーシスを誘発しおよび／または炎症反応を低下するためのアルギニン・デイミナーゼに富む細菌の使用、および該細菌を含有する医薬組成物または健康食組成物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US6572854B1 (enExample) |
| EP (1) | EP1058725B1 (enExample) |
| JP (1) | JP4253439B2 (enExample) |
| KR (1) | KR100594569B1 (enExample) |
| CN (1) | CN1189560C (enExample) |
| AR (2) | AR020053A1 (enExample) |
| AT (1) | ATE391774T1 (enExample) |
| AU (1) | AU754483B2 (enExample) |
| BR (1) | BR9815677A (enExample) |
| CA (1) | CA2321263C (enExample) |
| CY (1) | CY1108112T1 (enExample) |
| DE (1) | DE69839351T2 (enExample) |
| DK (1) | DK1058725T3 (enExample) |
| EA (1) | EA006018B1 (enExample) |
| ES (1) | ES2303357T3 (enExample) |
| IL (1) | IL137799A (enExample) |
| IN (2) | IN1999KO00116A (enExample) |
| IT (1) | IT1298918B1 (enExample) |
| MX (1) | MX237377B (enExample) |
| PT (1) | PT1058725E (enExample) |
| SI (1) | SI1058725T1 (enExample) |
| TR (1) | TR200002326T2 (enExample) |
| WO (1) | WO1999042568A1 (enExample) |
| ZA (1) | ZA9811619B (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1296148B1 (it) * | 1996-11-22 | 1999-06-09 | Renata Maria Anna Ve Cavaliere | Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte |
| US8697051B2 (en) * | 1999-06-09 | 2014-04-15 | Vsl Pharmaceuticals Inc. | Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
| IT1311495B1 (it) * | 1999-06-09 | 2002-03-13 | Mendes S U R L | Composizione comprendente sfingomielinasi alcalina, utilizzabile qualeprodotto dietetico, integratore alimentare o medicamento. |
| IT1306716B1 (it) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori. |
| AUPQ415899A0 (en) * | 1999-11-19 | 1999-12-16 | Vasse Research Institute Pty Ltd | Compositions for and methods of treatment of allergic diseases |
| HU227086B1 (en) * | 1999-11-25 | 2010-06-28 | Vakcina Kft | Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia |
| FR2809312B1 (fr) * | 2000-05-25 | 2002-07-12 | Gervais Danone Sa | Utilisation de l. casei dans des compositions immunostimulantes |
| US6767537B2 (en) * | 2000-05-26 | 2004-07-27 | Phil Arnold Nicolay | Composition and method for the treatment of sinusitis |
| US20040241149A1 (en) * | 2001-09-05 | 2004-12-02 | Claudio De Simone | Use of unmethylatd cpg |
| ITRM20010763A1 (it) | 2001-12-21 | 2003-06-21 | Simone Claudio De | Nuovo ceppo di batterio lattico e composizioni commestibili, farmaci e prodotti veterinari che lo contengono. |
| JP4733393B2 (ja) * | 2002-11-18 | 2011-07-27 | ポラリス・グループ | インビボでウイルス複製を阻害する方法 |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
| TW200700074A (en) * | 2005-03-04 | 2007-01-01 | Calpis Co Ltd | Inducer of t cell apoptosis |
| WO2006130187A1 (en) | 2005-05-31 | 2006-12-07 | The Iams Company | Feline probiotic lactobacilli |
| JP4938006B2 (ja) | 2005-05-31 | 2012-05-23 | ザ・アイムス・カンパニー | ネコ科動物プロバイオティク・ビフィドバクテリア |
| MX2009006887A (es) | 2006-12-21 | 2009-08-27 | Calpis Co Ltd | Agentes para promover la produccion de iga. |
| CN100584940C (zh) * | 2007-05-17 | 2010-01-27 | 江南大学 | 一株产精氨酸脱亚氨酶的菌种及其应用 |
| JP5247120B2 (ja) * | 2007-11-02 | 2013-07-24 | 雪印メグミルク株式会社 | Ｌ−オルニチン含有物の製造方法 |
| EE05341B1 (et) * | 2008-05-13 | 2010-08-16 | O� Tervisliku Piima Biotehnoloogiate Arenduskeskus | Isoleeritud mikroorganismi tvi Lactobacillus plantarum Inducia DSM 21379 kui organismi loomulikku kaitsev?imet t?stev probiootik, seda sisaldav toiduaine ja kompositsioon ning mikroorganismi kasutamine rakulist immuunsust t?stva ravimi valmistamisek |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| CN101606952B (zh) * | 2008-06-17 | 2012-09-19 | 上海交通大学医学院附属第三人民医院 | 乳双歧杆菌在制备预防泌尿系统结石药物中的应用 |
| JP5526320B2 (ja) * | 2008-09-04 | 2014-06-18 | 国立大学法人旭川医科大学 | 腸管保護剤 |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
| ES2575246T3 (es) | 2009-10-22 | 2016-06-27 | Kabushiki Kaisha Yakult Honsha | Lactobacillus casei para uso en la reducción del riesgo de desarrollar cáncer |
| JP5660508B2 (ja) * | 2010-04-08 | 2015-01-28 | 国立大学法人旭川医科大学 | 腸管保護剤 |
| KR101062779B1 (ko) | 2010-04-28 | 2011-09-06 | 삼육대학교산학협력단 | 충치 유발 세균의 성장 억제 활성을 나타내는 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 및 상기 비피도박테리움 아돌레센티스 ｓｐｍ1005 균주 또는 이의 배양물을 유효 성분으로 하는 충치 예방용 식품 및 약제학 조성물 |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| CN102433290B (zh) * | 2012-01-16 | 2013-06-12 | 江南大学 | 一株产瓜氨酸的菌株及用该菌株生物合成瓜氨酸的方法 |
| TW201611843A (en) | 2012-04-04 | 2016-04-01 | Polaris Group | Methods of treatment with arginine deiminase |
| CA2901795C (en) | 2013-03-15 | 2022-08-02 | Polaris Group | Arginine deiminase with reduced cross-reactivity toward adi - peg 20 antibodies for cancer treatment |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| JP6535285B2 (ja) * | 2014-01-22 | 2019-06-26 | 株式会社明治 | シトルリンの調製方法 |
| CN106794229B (zh) | 2014-03-18 | 2020-12-18 | 瑞华药业集团 | 工程化嵌合聚乙二醇化adi和使用方法 |
| CN114522225B (zh) | 2014-09-16 | 2025-07-25 | 瑞华药业集团 | 用于癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶 |
| HRP20180847T1 (hr) | 2014-12-23 | 2018-08-24 | 4D Pharma Research Limited | Pirinski polipeptid i imunološka modulacija |
| WO2016102950A1 (en) | 2014-12-23 | 2016-06-30 | 4D Pharma Research Limited | Immune modulation |
| RS59446B1 (sr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| EP3662917A1 (en) | 2015-06-15 | 2020-06-10 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| PL3650033T3 (pl) | 2015-06-15 | 2022-05-16 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| PL3209310T3 (pl) | 2015-11-20 | 2018-08-31 | 4D Pharma Research Limited | Kompozycja zawierająca szczepy bakteryjne |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| CN106994134B (zh) * | 2016-01-25 | 2020-08-25 | 深圳华大生命科学研究院 | 肠道益生菌在预防和/或治疗糖尿病及其相关疾病中的应用 |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| MD3313423T2 (ro) | 2016-03-04 | 2019-10-31 | 4D Pharma Plc | Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale |
| CN119950689A (zh) | 2016-07-05 | 2025-05-09 | 北极星药业集团股份有限公司 | 使用精氨酸耗竭剂的组合癌症免疫疗法 |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| EP3534963B1 (en) | 2016-11-02 | 2024-04-17 | Polaris Group | Formulations of pegylated arginine deiminase |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| WO2018125735A1 (en) * | 2016-12-29 | 2018-07-05 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
| CN108265068B (zh) * | 2016-12-31 | 2021-06-15 | 江苏众红生物工程创药研究院有限公司 | 重组精氨酸脱亚胺酶及其产业化制备方法和应用 |
| CA3064171A1 (en) | 2017-05-22 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| WO2018215782A1 (en) | 2017-05-24 | 2018-11-29 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
| JP6840272B2 (ja) | 2017-06-14 | 2021-03-10 | フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ | 細菌株を含む組成物 |
| HRP20201629T1 (hr) | 2017-06-14 | 2020-12-25 | 4D Pharma Research Limited | Sastavi koji sadrže bakterijski soj roda megasphaera i njihove upotrebe |
| MA49373B1 (fr) | 2017-06-14 | 2021-02-26 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| RU2675110C1 (ru) * | 2018-04-09 | 2018-12-17 | Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) | Фармацевтическая композиция для терапии воспалительных заболеваний слизистых оболочек кишечника на основе штамма Lactobacillus brevis 47f, проявляющая местную противовоспалительную активность |
| FR3082207B1 (fr) | 2018-06-06 | 2022-03-25 | Agronomique Inst Nat Rech | Nouvelle souche probiotique de lactobacillus brevis |
| KR102069622B1 (ko) * | 2019-06-25 | 2020-01-23 | 한국식품연구원 | 락토바실러스 퍼멘텀 WiKim0102를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR20230004505A (ko) * | 2020-04-17 | 2023-01-06 | 클라우디오 드 시모네 | 기도 질환의 치료 및 예방에서 세균 조성물의 용도 |
| CN115916230A (zh) * | 2020-06-22 | 2023-04-04 | 株式会社明治 | 用于促进白细胞介素-10产生的组合物 |
| KR102363111B1 (ko) * | 2021-06-29 | 2022-02-15 | (주)바이오일레븐 | 항염 및 항산화 활성을 갖는 락토바실러스 퍼멘텀 균주 및 이의 용도 |
| KR102822265B1 (ko) * | 2023-02-27 | 2025-06-19 | 퓨리셀매니아 주식회사 | 신규 락토바실러스 브리비스 균주 및 이의 용도 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4415550A (en) * | 1983-03-04 | 1983-11-15 | Pakhomov Gennady N | Treatment-and-prophylactic tooth paste possessing anticarious effect |
| JP2900279B2 (ja) * | 1989-08-02 | 1999-06-02 | 株式会社ジャパンエナジー | 新規なアルギニンデイミナーゼ、その製造法及び該酵素を有効成分とする制癌剤 |
| US5196195A (en) * | 1990-03-27 | 1993-03-23 | Cornell Research Foundation, Inc. | Use of arginase to control nitric oxide formation |
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| AUPM596894A0 (en) * | 1994-05-30 | 1994-06-23 | Hybrid Scientific Pty Ltd | Composition for treating gastrointestinal disorders - a combination of bismuth salts plus lactobacillus or bifidobacteria species bacteria for treating gastrointestinal disorders |
| US5599795A (en) * | 1994-08-19 | 1997-02-04 | Mccann; Michael | Method for treatment of idiopathic inflammatory bowel disease (IIBD) |
-
1998
- 1998-02-20 IT IT98RM000103A patent/IT1298918B1/it active IP Right Grant
- 1998-10-13 SI SI9830908T patent/SI1058725T1/sl unknown
- 1998-10-13 ES ES98950301T patent/ES2303357T3/es not_active Expired - Lifetime
- 1998-10-13 AT AT98950301T patent/ATE391774T1/de active
- 1998-10-13 PT PT98950301T patent/PT1058725E/pt unknown
- 1998-10-13 US US09/601,533 patent/US6572854B1/en not_active Expired - Lifetime
- 1998-10-13 TR TR2000/02326T patent/TR200002326T2/xx unknown
- 1998-10-13 AU AU96441/98A patent/AU754483B2/en not_active Expired
- 1998-10-13 BR BR9815677-2A patent/BR9815677A/pt active Search and Examination
- 1998-10-13 EP EP98950301A patent/EP1058725B1/en not_active Expired - Lifetime
- 1998-10-13 KR KR20007008973A patent/KR100594569B1/ko not_active Expired - Fee Related
- 1998-10-13 DK DK98950301T patent/DK1058725T3/da active
- 1998-10-13 DE DE69839351T patent/DE69839351T2/de not_active Expired - Lifetime
- 1998-10-13 CN CNB988137054A patent/CN1189560C/zh not_active Expired - Lifetime
- 1998-10-13 IL IL13779998A patent/IL137799A/xx not_active IP Right Cessation
- 1998-10-13 JP JP2000532508A patent/JP4253439B2/ja not_active Expired - Fee Related
- 1998-10-13 EA EA200000856A patent/EA006018B1/ru not_active IP Right Cessation
- 1998-10-13 WO PCT/IT1998/000275 patent/WO1999042568A1/en not_active Ceased
- 1998-10-13 CA CA002321263A patent/CA2321263C/en not_active Expired - Lifetime
- 1998-12-18 ZA ZA9811619A patent/ZA9811619B/xx unknown
-
1999
- 1999-01-08 AR ARP990100064A patent/AR020053A1/es active IP Right Grant
- 1999-02-15 IN IN116KO1999 patent/IN1999KO00116A/en unknown
- 1999-02-15 IN IN117CA1999 patent/IN188450B/en unknown
-
2000
- 2000-08-16 MX MXPA00007990 patent/MX237377B/es active IP Right Grant
-
2003
- 2003-03-28 US US10/400,675 patent/US7147847B2/en not_active Expired - Fee Related
-
2008
- 2008-06-03 CY CY20081100582T patent/CY1108112T1/el unknown
-
2009
- 2009-05-19 AR ARP090101791A patent/AR071841A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4253439B2 (ja) | アポトーシスを誘発しおよび／または炎症反応を低下するためのアルギニン・デイミナーゼに富む細菌の使用、および該細菌を含有する医薬組成物または健康食組成物 | |
| EP0760848B1 (en) | Lactobacillus strains of human origin, their compositions and uses thereof | |
| JP2012040015A (ja) | 食養生製品、食品添加物または医薬用アルカリ性スフィンゴミエリナーゼ含有組成物 | |
| EP2270133B1 (en) | Method for obtaining a novel strain of bifidobacterium bifidum with activity against infection by helicobacter pylori | |
| US9439953B2 (en) | Compositions comprising alkaline sphingomyelinases for use as a dietetic preparation, food supplement or pharmaceutical product and methods for using them | |
| JP2003501399A5 (enExample) | ||
| HK1033338B (en) | Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria | |
| EA043487B1 (ru) | Штамм bifidobacterium bifidum 8, используемый в качестве пробиотика | |
| HK1127906A (en) | Composition comprising alkaline sphingomyelinase for use as a dietetic preparation, food supplement or pharmaceutical product |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20050628 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050811 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080805 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081105 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081112 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081205 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090106 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090126 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120130 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130130 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140130 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| S534 | Written request for registration of change of nationality |
Free format text: JAPANESE INTERMEDIATE CODE: R313534 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |